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Abstract
Semaphorin 3B (SEMA3B) is a secreted axonal guidance molecule that is expressed during 
development and throughout adulthood. Recently, SEMA3B has emerged as a tumor suppressor in 
non-neuronal cells. Here we show that SEMA3B is a direct target of GATA3 transcriptional 
activity. GATA3 is a key transcription factor that regulates genes involved in mammary luminal 
cell differentiation and tumor suppression. We show that GATA3 relies on SEMA3B for 
suppression of tumor growth. Loss of SEMA3B renders GATA3 inactive and promotes aggressive 
breast cancer development. Overexpression of SEMA3B in cells lacking GATA3 induces a 
GATA3-like phenotype and higher levels of SEMA3B are associated with better cancer patient 
prognosis. Moreover, SEMA3B interferes with activation of LIM kinases (LIMK1 and LIMK2) to 
abrogate breast cancer progression. Our data provide new insights into the role of SEMA3B in 
mammary gland and provides a new branch of GATA3 signaling that is pivotal for inhibition of 
breast cancer progression and metastasis.
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Introduction
Semaphorins function as short-range axonal guidance molecules(1). There are eight classes 
of semaphorins, and class-3 semaphorins are the only secreted group in vertebrates(2). 
Within class-3, there are seven semaphorin members that belong to semaphorin/collapsin 
family and exert their cellular effects through binding to neuropilins and plexin receptor 
family members(2, 3). SEMA3B is a secreted molecule that contains a highly conserved 
Sema domain in the amino terminus. Interaction between semaphorins and their receptors 
leads to changes in cytoskeletal architecture and cellular motility through influencing the 
activation state of various Rho GTPases in a targeted cell(4–9). Semaphorins along with 
other axonal guidance molecules function as environmental cues to allow proper innervation 
of neurons by either permitting or inhibiting their growth, thereby guiding neurites migration 
along a correct path during nervous system development.
While SEMA3B was initially discovered as an inhibitory axonal guidance molecule, recent 
findings suggest that SEMA3B also functions as a tumor suppressor in lung, renal, gastric 
and potentially breast tissues(10–14). In the mammary gland, SEMA3B is present in both 
luminal and basal epithelial cells(3). However, the importance of SEMA3B in maintenance 
of mammary epithelial cell homeostasis remains unclear.
We and others previously showed that GATA3 is essential for driving mammary epithelial 
cell differentiation and maintaining mammary gland homeostasis(15–18). GATA3 belongs to 
GATA family of transcription factors that play fundamental roles as master regulators of 
cellular differentiation and homeostasis in various tissues(15, 19–22). The GATA family is 
comprised of six members that are expressed in a tissue-specific manner(23). All GATA 
family members contain two transactivation domains in the amino terminus and two 
conserved zinc finger domains at the carboxyl terminus. In addition to their structural 
similarities, GATA family members recognize and bind to a consensus DNA sequence (A/
T)GATA(A/G) to regulate downstream target genes(24).
Loss of or mutations in GATA3 results in development of aggressive breast cancer(25–30). 
Indeed, GATA3 is one of the top three mutated genes in breast cancer patients(16), 
emphasizing its importance in tumor development. Therefore identifying new GATA3 
downstream target genes provides valuable information in discovering new cancer 
biomarkers and potential therapeutic strategies for prevention of breast cancer.
In the present study, we establish SEMA3B as a new GATA3 downstream target gene that is 
indispensible for GATA3 tumor suppressive activity. In the absence of GATA3, elevated 
SEMA3B levels independently interfere with aggressive tumor growth and higher SEMA3B 
levels is associated with better breast cancer patient prognosis. We also show that SEMA3B 
interferes with activation of LIM kinases (LIMK1 and LIMK2) that are known Rho GTPases 
downstream targets. Inhibition of LIMK1/2 activation provides a molecular mechanism for 
inhibition of breast cancer progression via SEMA3B. Our findings highlight the importance 
of SEMA3B as a GATA3 downstream target gene and provide a new mechanism for driving 
tumor suppression in mammary epithelial cells.
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Results
In silico Analysis of Breast Cancer Patient Samples Demonstrates a Correlation Between 
Expression of GATA3 and SEMA3B
We initially performed in silico gene expression analysis by utilizing The Cancer Genome 
Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) databases to determine the global gene expression alterations that correlate 
with changes in GATA3 levels. Gene expression analysis of 597 breast cancer samples as 
well as RNAseq analysis of 1215 tumor samples from TCGA database indicated a strong 
correlation between loss of GATA3 and downregulation of SEMA3B (Fig. 1a and 
Supplementary Figure 1 and 2). To demonstrate the validity of our analysis, we also 
included the expression analysis of a pro-tumor gene MYC that is upregulated in the absence 
of GATA3 expression (Fig. 1a). TCGA database analysis using Regulome Explorer (http://
www.cancerregulome.org/) indicated that SEMA3B resides in the same protein network as 
GATA3 and several other key proteins such as BCL2, ESR1, CCNB1 and AR (Fig. 1b) and 
suggested a possible link between GATA3 levels and SEMA3B expression during breast 
cancer development.
To investigate a potential role for SEMA3B in breast cancer development, we performed 
analysis using a public microarray dataset (GSE9014). The data suggest that SEMA3B is 
significantly downregulated in the samples from patients with invasive breast carcinoma 
(Fig. 1c). Similarly, comparison of SEMA3B expression in normal versus triple negative 
breast cancer samples using the TCGA database also indicated significant SEMA3B 
downregulation in triple negative breast cancer patients (Fig. 1d). We also examined 
SEMA3B levels across PAM50 breast cancer subtypes using METABRIC database (Fig. 1e) 
showing that SEMA3B levels remain high in luminal cancers. However, SEMA3B levels 
decreases significantly in basal subtypes (Fig. 1e). This analysis in PAM50 subtypes 
reinforces the importance of SEMA3B and suggests a correlation between the loss of 
GATA3 and SEMA3B levels during aggressive breast cancer formation. Moreover, there was 
a correlation between SEMA3B and breast cancer progression, with decreasing expression 
levels of SEMA3B as the tumors progress from stage I to stage IV (Suppl. Fig. 3). We 
observed a similar trend in downregulation of SEMA3B expression when we compared low-
grade tumors to higher-grade tumors in the affected patients (Suppl. Fig. 4). Finally, analysis 
of the van’t Veer breast cancer database for breast cancer survival outcome(31) indicated a 
poorer prognosis for patients with lowered SEMA3B expression (Fig. 1f). Collectively, the 
in silico analysis of breast cancer patient samples provides clues to a potential role for 
SEMA3B during breast cancer development and suggests an interplay between GATA3 and 
SEMA3B.
GATA3 Directly Controls SEMA3B Expression
To decipher whether GATA3 directly or indirectly controls SEMA3B levels, we performed 
in silico analysis using the ENCODE ChIP-Seq database. We searched for potential 
promoter sequences that contain a GATA3 binding site and found that the SEMA3B 
promoter is a potential target of GATA3 (Suppl. Fig. 5). We then performed chromatin 
immunoprecipitation analysis (ChIP) in three different transiently transfected mammary cell 
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lines, EpH4.9, T47D and MDA-MB-231 to examine whether GATA3 directly targets 
SEMA3B promoter. We found that in all these cell lines, GATA3 binds to the SEMA3B 
promoter (Fig. 2a). Next, we overexpressed GATA3 in MDA-MB-231 cells and monitored 
alterations in SEMA3B expression levels. The control MDA-MB-231 cells exhibited 
minimal GATA3 and SEMA3B expression. However, overexpression of GATA3 resulted in 
significant upregulation of SEMA3B in the MDA-MB-231 cells (Fig. 2b and 2c). 
Additionally, immunostaining analysis demonstrated higher SEMA3B levels in cells 
overexpressing GATA3 when compared to control cells (Fig. 2d).
To study the GATA3 signaling pathway, we examined the relationship between GATA3 and 
SEMA3B in NMuMG cells that exhibit high levels of endogenous GATA3 expression. 
Knockdown of endogenous GATA3 levels using a specific siRNA resulted in lowering 
SEMA3B expression levels, suggesting a correlation between GATA3 and SEMA3B levels 
in mammary cells (Fig. 2e). Taken together, these data indicate that in mammary epithelial 
cells, GATA3 directly binds to SEMA3B promoter and positively regulates SEMA3B 
expression.
GATA3 Relies on Intact SEMA3B Expression to Inhibit Cellular Migration and Proliferation
To investigate the interplay between GATA3 and SEMA3B, we generated multiple MDA-
MB-231 stable cell lines that either expressed the control shRNA MDA-MB-GATA3-PLKO 
(MDA-GATA3) or shRNA targeting SEMA3B (MDA-GATA3-SEMA3BKD). In 2D culture, 
cells overexpressing GATA3 lost their spindle-like morphology and became more cuboidal 
(luminal epithelial-like) (Fig. 3a), as we described previously(32). Moreover, the MDA-
GATA3 cells formed tight colonies as opposed to the more dispersed colonies of control 
cells (Fig. 3a). Intriguingly, in the absence of SEMA3B, the GATA3 overexpressing cells 
reverted back to spindle-like morphology and resembled MDA-MB-231 (control) colonies 
that lacked GATA3 expression (Fig. 3a).
We also examined the effect of SEMA3B overexpression independent of GATA3 signaling 
in MDA-MB-231 cells. Since SEMA3B is downstream of GATA3, we were interested to 
determine whether SEMA3B could mimic GATA3 activity. Therefore, we generated MDA-
MB-231 cells that either contained the control plasmid, MDA-MB-231-pEIZ (Control) or 
overexpressed SEMA3B, MDA-MB-231-SEMA3B (MDA-SEMA3B). Upon overexpression 
SEMA3B alone, MDA-MB-231 cells mimicked GATA3 overexpressing cells and formed 
tight cuboidal colonies (Fig. 3a). In three-dimensional (3D) Matrigel cultures, MDA-
MB-231 (control) cells formed invasive colonies rich in invadopodia. However, upon 
overexpression of GATA3, the cells formed dense spherical colonies with minimal 
invadopodia (Fig. 3b). Upon overexpression of SEMA3B alone, MDA-MB-231 cells formed 
less invasive GATA3-like colonies, recapitulating the GATA3 phenotype (Fig. 3b). 
Interestingly, knockdown of SEMA3B even in the presence of GATA3 expression rescued 
the invasive phenotype and the colonies resembled the parental MDA-MB-231 cells (Fig. 
3b). To show that these observations are not exclusive to MDA-MB-231 cells, we examined 
the effect of SEMA3B knockdown in EpH4.9 mammary epithelial cells. EpH4.9 cells have 
detectable endogenous GATA3 and SEMA3B levels and in 3D Matrigel cultures form dense 
colonies that exhibit minimal invadopodia. Again, knockdown of SEMA3B in EpH4.9 cells 
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resulted in formation of aggressively invasive colonies when compared to control (Suppl. 
Fig. 6). These observations indicate that SEMA3B plays a significant role in disrupting 
cellular invasiveness in mammary epithelial cell. Furthermore, GATA3 signaling requires 
intact SEMA3B to disrupt the invasive phenotype observed in MDA-MB-231 cells.
Next we examined the effect of SEMA3B on expression levels of epithelial to mesenchymal 
transition (EMT)-associated genes. Since SEMA3B inhibits cellular invasiveness and 
reduction in SEMA3B levels forms invasive colonies it is possible the SEMA3B could 
modulate EMT-associated genes. qPCR analysis in control and MDA-SEMA3B cells 
indicated that SEMA3B expression leads to reduction of the EMT genes Vimentin, 
Fibronectin, Snail and N-Cadherin expression levels (Fig. 3c), while, SEMA3B increasing 
E-cadherin expression (Fig. 3c). These results suggest that SEMA3B increases cell-cell 
interaction by lowering EMT genes and increasing E-cadherin levels.
To examine the effect of GATA3/SEMA3B signaling on MDA-MB-231 cell motility, we 
performed a scratch assay. MDA-MB-231 (control) cells were able to close the generated 
gap within 24 hours (Fig. 3d). However, MDA-MB-231 cells expressing either GATA3 or 
SEMA3B failed to fill the gap within the same time span (Fig. 3d). The observation suggests 
that GATA3 and SEMA3B interfere with cellular migration in MDA-MB-231 cells. 
Interestingly, MDA-GATA3-SEMA3BKD cells closed the generated gap, similar to MDA-
MB-231 parental cells, within 24 hours (Fig. 3d). These data suggest that GATA3 signaling 
relies on the presence of SEMA3B to inhibit cellular migration.
Next, we examined the effect of GATA3 and SEMA3B interplay in cellular proliferation 
using a colony formation assay in 2D cultures. Overexpression of SEMA3B resulted in 
formation of fewer colonies when compared to control (Fig. 3e). Inhibition of cellular 
proliferation and colony formation in cells expressing SEMA3B mirrored MDA-GATA3 
cells. However, removal of SEMA3B in cells with intact GATA3 signaling restored cellular 
proliferation and colony formation (Fig. 3e; Suppl. Fig. 7). We observed similar behavior in 
mammary MCF7 tumor cells. Expression of SEMA3B significantly inhibited colony 
formation when compared to control. However, knockdown of SEMA3B even in presence of 
GATA3, rescued proliferative phenotype in MCF7 tumor cells (Suppl. Fig. 8).
Taken together, our in vitro data suggest that the presence of SEMA3B is pivotal for 
effective GATA3 signaling and intact GATA3/SEMA3B signaling axis is essential for 
inhibition of abnormal cellular migration and proliferation.
Tumor Suppressive Activity Exerted by GATA3 Requires Intact SEMA3B Expression
To determine the necessity of SEMA3B in GATA3 tumor suppressive activity, we 
orthotopically transplanted the MDA-MB-231 stable cell lines via intra-mammary gland 
injection into 8-week-old female nude mice. To examine the role of SEMA3B independent 
of GATA3 signaling in tumor growth, we compared control (SEMA3B-low) to MDA-
SEMA3B (SEMA3B-high) cell transplants. Overexpression of SEMA3B reduced tumor 
growth and resulted in the formation of significantly smaller tumors when compared to 
control (Fig. 4a). To further elaborate on the importance of SEMA3B as a signal transducer 
molecule downstream of GATA3, we also transplanted tumor cells expressing GATA3 with 
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or without the intact SEMA3B molecule. Tumor cells overexpressing GATA3 demonstrated 
slower tumor growth and smaller tumor size(17, 25, 26, 29, 31, 32). In our transplant 
experiments, analysis of tumor sizes indicated that MDA-GATA3-SEMA3BKD cells give 
rise to significantly larger tumors when compared to tumors from MDA-GATA3 cells. These 
results suggest the need for presence of SEMA3B for proper GATA3 tumor suppressive 
activity (Fig. 4b). Thus, in vivo SEMA3B mimics GATA3 activity in hindering tumor 
growth. We also performed Ki67 staining to assess the cellular proliferation status of the 
tumor cells in our samples. Cells in control tumors stained strongly for Ki67, while MDA-
GATA3 or MDA-SEMA3B tumors had many fewer Ki67 positive cells (Fig. 4c). Sections 
from MDA-GATA3-Sema3BKD tumors had more intense Ki67 staining than MDA-GATA3 
or MDA-SEMA3B tumor sections. Knockdown of SEMA3B in tumor cells expressing 
GATA3 restored the proliferative ability of tumor cells and support the observations that 
GATA3 relies on SEMA3B to transduce its tumor suppressive activity (Fig. 4c).
SEMA3B Decreases Tumor Metastasis
The most significant factor in breast cancer aggressiveness is its propensity to metastasize. 
Therefore, we asked whether SEMA3B regulated metastasis of MBA-MB-231 tumors. We 
investigated tumor cell metastasis to inguinal lymph nodes in the orthotopically transplanted 
mice. Mice with control MDA-MB-231 or MDA-SEMA3BKD tumors had significantly 
larger lymph nodes, larger lymph node metastatic colonies and higher number of metastatic 
cells in the lymph nodes than the mice with tumors expressing GATA3 or SEMA3B (Fig 4d, 
e). Thus our data suggest that SEMA3B can interfere with tumor metastasis.
Previous studies have indicated that semaphorins can regulate cell migration through Rho 
family of small GTPases (4–9). Recent reports indicate that LIM kinases (LIMK1 and 
LIMK2) that are downstream targets of Rho GTPases, play a role in enhancing breast cancer 
progression and metastasis(33–37). Since SEMA3B interferes with breast cancer 
progression, we asked whether SEMA3B influences LIMK1 and LIMK2 activity. Functional 
activation of LIM kinases requires phosphorylation at LIMK1 (threonine 508) and LIMK2 
(threonine 505) (38, 39). We analyzed phospho-LIMK1/2 in control MDA-MB-231 and 
MDA-SEMA3B cells. Western blot analysis indicated that SEMA3B reduces phospho-
LIMK1/2 levels when compared to control (Fig. 4f). Reduction of phopho-LIMK1/2 
suggests one potential mechanism whereby SEMA3B could inhibit breast cancer 
progression and metastasis.
Collectively, our experiments support the importance of SEMA3B as a component of 
GATA3 signaling axis in mammary cells and provide evidence that SEMA3B can inhibit 
tumor growth as well as tumor metastasis downstream of GATA3 signaling.
Discussion
SEMA3B was originally identified as a neurite guidance molecule during nervous system 
development. However, recently, alternative roles for SEMA3B in non-neuronal adult cells 
have been described, highlighting the diverse functionality of developmental genes in an 
adult organism. In this study we have shown that SEMA3B is a direct target of he 
transcription factor GATA3 and that loss of SEMA3B correlates with aggressive mammary 
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tumor development and progression. GATA3 plays a fundamental role in maintaining 
mammary gland homeostasis by promoting luminal epithelial cell differentiation and also 
acts as a tumor suppressor by transcriptional regulation to influence the expression of a 
plethora of genes including pro-tumor factors (32). Our tumor transplant data indicates that 
overexpression of SEMA3B interferes with tumor metastasis similar to tumors expressing 
GATA3. By experimental analyses we showed that downregulation of SEMA3B leads to 
cellular proliferation, tumor growth and enhanced tumor invasiveness, even in presence of 
intact GATA3. We also show that SEMA3B inhibits tumor invasiveness by downregulating 
EMT-associated genes and increasing E-cadherin levels. Additionally, we found that 
SEMA3B, inhibits phosphorylation and subsequent activation of LIMK1/2. LIMK1/2 have 
been shown to promote breast cancer progression, therefore inhibition of LIMK1/2 is one 
potential mechanism for SEMA3B to exert inhibitory effects during breast cancer 
progression.
SEMA3B is a secreted molecule and it is important to consider its tumor suppressive 
influence beyond its potential autocrine functions. It is likely that other SEMA3B producing 
cells in the tumor microenvironment could influence the behavior of tumor cells. Loss of 
SEMA3B expression in cells of tumor microenvironment as well as tumor cells themselves 
could result in formation of aggressive breast cancer. To that extent, we hypothesize that the 
GATA3/SEMA3B signaling presents an important regulatory pathway that directs anti-tumor 
activity in the mammary gland.
The fact that a neuronal specific gene such as SEMA3B could influence mammary gland 
homeostasis is intriguing, building on other examples of such diversity. For example SLITs 
and their receptor ROBO were originally identified as axonal guidance signaling molecules 
during development(40, 41), but have been shown to play alternative roles in mammary 
gland branching(42), mammary stem cell self-renewal(43) and breast cancer 
development(44).
Recently, GATA3 has emerged as one of top three genes associated with breast cancer 
development. Thus, uncovering new GATA3 signaling axes could help to better understand 
breast cancer development. Previously, we have shown that tumor suppressive activity of 
GATA3 is partially mediated through direct upregulation of miR-29b(32). miR-29b 
functions as a signal transducer of GATA3 and directs many anti-tumor activities via 
targeting a collection of genes that are involved in angiogenesis and remodeling the tumor 
microenvironment. Preliminary studies indicate that induction of SEMA3B via GATA3 is 
independent miR-29b. Our findings suggest that GATA3 induces multiple anti-tumor 
pathways to inhibit mammary tumor development. Redundant regulatory pathways could 
provide a safeguard for proper cellular functioning. The GATA3/SEMA3B signaling could 
function in parallel with other pathways such as GATA3/miR-29b to ensure proper cellular 
function in mammary epithelial cells.
There are several possibilities as to how lack of SEMA3B expression could override GATA3 
activity. SEMA3B forms a complex with neuropilins and plexins on the cell surface. VEGF-
A also binds to neuropilins and this complex promotes cellular migration(45, 46). In tumor 
cells, upregulation of SEMA3B via GATA3 could push the competition for neuropilin 
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binding to favor SEMA3B. In turn, elevated SEMA3B levels could outcompete VEGF-A for 
binding to neuropilins, thereby disrupting tumor cell migration. Additionally, since 
SEMA3B can inhibit phosphatidylinositol 3-kinase (PI3K)/Akt(47), upregulation of 
SEMA3B by GATA3 could result in downregulation of PI3K/Akt activity and lead to 
inhibition of cellular proliferation and tumor growth.
Collectively, our data shed new insights into better understanding of GATA3 pathway in the 
mammary gland. We identified SEMA3B as a direct target of the GATA3 transcription factor 
and highlighted its importance as a signal transducer molecule. Loss of SEMA3B overrides 
GATA3’s instructive ability to function as a tumor suppressor and designates SEMA3B as an 
integral part of GATA3 pathway in mammary epithelial cells. Our findings introduce 
SEMA3B as a molecular target that could potentially provide new therapeutic strategies 
against aggressive breast cancer.
Methods
Cell Culture and siRNA Constructs
T47D tumor cells (ATCC) were cultured in RPMI 1640 medium supplemented with 10% 
FBS, insulin and antibiotics. MDA-MB-231 cells (ATCC) were cultured in RPMI 1640 
supplemented with 10% FBS and antibiotics. EpH4.9 cells were cultured in DME-H21 
medium supplemented with 5% fetal bovine serum (FBS), insulin (5 μg/ml) and antibiotics. 
3D Matrigel culture assays were performed as described(32). The lentiviral SEMA3B 
shRNA constructs were generous gift from Dr. Luca Tamagnone. The purchased siRNA 
sequences were as follows: ON-TARGETplus GATA3 siRNA (Dharmacon). SEMA3B 
siRNA (Santa Cruz Biotechnology INC.).
Immunostaining, Histology and Antibodies
Immunofluorescence—Cells were cultured on coverslips prior to staining. Cells were 
washed with cold PBS and fixed with 4% paraformaldehyde for 20 min. Cells were washed 
with cold PBS and blocked with PBS, 5% goat serum and 0.25% Triton X-100 for at least 1 
hour at room temperature. Coverslips were incubated with primary antibody diluted in PBS 
plus 5% goat serum overnight at 4°C. Coverslips were washed with PBS and incubated with 
secondary antibody for 1 hour at room temperature then washed with PBS and mounted with 
Vectashield mounting medium with DAPI (Vector Laboratories).
Immunohistochemistry—Tissues were fixed in 4% paraformaldehyde overnight and 
embedded in paraffin. Tissues were sectioned into 5–7 μm sections and a standard protocol 
for hematoxylin and eosin staining was used for histological analysis. Immunostaining was 
performed using the sodium citrate protocol for antigen retrieval as previously described 
(15). Images were captured using Nikon C1si confocal microscope.
Antibodies—Actin-HRP (cs-47778, Santa Cruz Biotechnology), Alexa Fluor 546 goat 
anti-mouse (A-11008, ThermoFisher Scientific), Alexa Fluor 488 goat anti-rabbit (A-11030, 
ThermoFisher Scientific), GATA3 (AF2605, R&D Systems, Ki67 (ab15580, Abcam), 
Sema3B (sc-21204-R, Santa Cruz Biotechnology). Phoshop-LIMK1 (Thr508)/LIMK2 
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(Thr505) (3841T, Cell Signaling Technology). LIMK1 (VMA00361KT, Bio-Rad 
Laboratories Inc.). LIMK2 (8C11) (3845, Cell Signaling Technology).
Bioinformatics and Computational Analysis
SEMA3B expression analysis in human breast cancer and normal tissues was performed 
using the Oncomine database (www.oncomine.org). Statistical analysis was performed via 
Oncomine default algorithms(48). The TCGA data set obtained from Oncomine is 
embedded in the TCGA database (https://tcga-data.nci.nih.gov/tcga)(49). Heatmaps were 
generated from breast cancer TCGA database. The GSE9014 dataset obtained from 
Oncomine is embedded in NCBI GEO database (http://www.ncbi.nlm.nih.gov/geo)(50) for 
SEMA3B expression analysis.
Kaplan–Meier log-rank tests were performed using default parameters in SurvExpress(51). 
Patient data was segregated into low or high SEMA3B expressing groups at the median 
expression value in all cases.
Promoter Analysis and Chromatin Immunoprecipitation Assay
SEMA3B promoter analysis was performed using the ENCODE ChIP-Seq data set. Primer 
sequences for ChIP analysis: Set #1, 5′-AGACAGGTATGACCGTGACC-3′ (forward) and 
5′-AGCTGTCTTGTGCTTGGGAAT-3′ (reverse); Set #2, 5′-
CAGACCTCATGGGACGAGAC-3′ (forward) and 5′-TGGCTAGCTGTCTTGTGCTT-3′ 
(reverse). GATA3 and SEMA3B chromatin immunoprecipitation analysis was performed 
using the ChIP-IT High-Sensitivity Kit as per manufacturer’s protocol (Active Motif).
Scratch Assay
Cells were seeded in 6-well plates at a density of 5×105 cells/well. After 24 hours, a 
monolayer of cells was scratched by a 200-μL pipette tip. Cell migration was quantified by 
counting the number of cells that had migrated to the scratched area within 24 hours.
Colony Formation Assay
Cells were seeded in 6-well plates at a density of 1×103 cells/well and cultured for 14 days. 
Cells were fixed using methanol and stained with Giemsa solution and colonies were 
counted.
Animal Studies
5×105 cells in 10 μl of 1:1 DMEM/Matrigel (BD Biosciences) were injected in the fat pads 
of female 8-week-old nude mice (Simonsen Laboratories). Once palpable, tumors were 
measured twice weekly and the tumor volumes were determined as follows: V = 0.52 × 
(length) 2 × width. All mouse procedures were approved by University of California, San 
Francisco, Institutional Animal Care and Use Committee.
Statistical Analysis
Statistical analysis was conducted using Prism 7 software (Graph Pad Software, Inc.). 
Statistical significance between two groups was calculated using Student’s t test, A one-way 
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analysis of variance (ANOVA) was performed to determine two or more group differences 
with Bonferroni test and P values < 0.05 were considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
In silico analysis of breast cancer databases. (a) Analysis of TCGA database. Heat map 
indicating gene expression analysis for GATA3, SEMA3B and MYC in multiple breast 
cancer samples. (N = 597) (b) Analysis of TCGA database via Regulome explorer. Data 
present a collection of proteins including GATA3 that may reside in the same protein 
network as SEMA3B. (c) Analysis of SEMA3B expression via the GSE9014 database. 
SEMA3B expression is significantly lowered in the invasive breast carcinoma samples. 
(Normal: N = 6, Invasive breast carcinoma: N = 53, P = 1.03E-21) (d) TCGA analysis 
indicating significantly lowered SEMA3B expression in triple negative breast cancer 
samples. (Normal: N = 244, Triple negative: N = 49, P = 4.06E-9) (e) Analysis of SEMA3B 
expression in PAM50 subtypes using the METABRIC database. Luminal breast cancers 
possess higher levels of SEMA3B expression than the basal subtype, P = <0.0001, Normal: 
N = 202, Luminal A: N = 721, Luminal B: N = 492. HER2: N = 240, Basal: N = 331) (f) 
Analysis of breast cancer patient survival (31). Tumor samples exhibiting lower SEMA3B 
expression show poorer patient prognosis. (Concordance index = 62.3, Log-rank equal 
curves P = 1.6E-4, R^ 2 = 0.005/0.941, Risk groups hazard ratio = 2.4, P = 2.61E-6)
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Figure 2. 
GATA3 directly controls SEMA3B expression. (a) ChIP analysis indicating GATA3 
transcription factor binding to SEMA3B promoter in EpH4.9, T47D and MDA-MB-231 
cells. (b) qPCR analysis of GATA3 and SEMA3B expression in MDA-MB-231 cells, N = 6. 
Overexpression of GATA3 in MDA-MB-231 cells results in elevation of SEMA3B levels. 
(c) Western blot analysis of MDA-MB-231 cell lysate. Overexpression of GATA3 enhances 
SEMA3B expression. (d) Immunostaining of MDA-MB-231 (control) and GATA3 
overexpressing MDA-MB-231 cells. Overexpression of GATA3 upregulates SEMA3B 
levels. Bar 50 μm. (e) qPCR analysis of SEMA3B in NMuMG cells, N = 2. Lowering 
GATA3 expression via siRNA results in downregulation of SEMA3B levels.
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Figure 3. 
Inhibition of cellular migration and proliferation by GATA3 relies on presence of SEMA3B. 
(a) Bright-field images of MDA-MB-231 stable cell lines in 2D cell cultures. Bar, 50 μm. 
(b) Phase-contrast images of MDA-MB-231 stable cell lines in 3D cultures. Arrows indicate 
the presence of invadopodia moving outward from the colony. Bar, 200 μm. (c) 
Quantification of 3D Matrigel culture colonies. (N = 7) (d) qRT-PCR analysis of EMT-
associated genes. RNA samples from MDA-MB-231 control and MDA-SEMA3B cells were 
collected. qRT-PCR analysis indicates that SEMA3B lowers EMT gene levels. SEMA3B 
enhanced E-cadherin levels compared to control. (e) Scratch assay analysis indicating 
difference in cellular migration in MDA-MB-231 stable cell lines. N = 6 (f) Quantification 
of cell infiltration of gaps between the two invading cell fronts. The gap was measured using 
ImageJ software. Y-axis indicates experimental group/control group. (N = 6). (g) Colony 
formation assay. MDA-MB-231 stable cell lines were cultured in 6-well plates to allow 
colony growth. Colonies were stained with crystal violet and counted. N = 12. (h) Graph 
representing the quantification of Giemsa stained colonies. (N = 12).
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Figure 4. 
Loss of SEMA3B disrupts GATA3 tumor suppressive activity. (a) MDA-SEMA3B and (b) 
MDA-GATA3-SEMA3BKD stable cell lines where transplanted in 8-week-old female nude 
mice via orthotopic injection. Color photographs show a representative set of gross tumors 
from each transplanted group. Graphs indicates tumor measurement during the course of 
experiment, N = 10 for each group. (c) Immunostaining and quantification analysis for Ki67 
expression in the tumor sections (N = 6). Bar, 100 μm. (d) Analysis of inguinal lymph node 
weight from transplanted mice, N = 10 for each group. (e) H&E analysis of lymph node 
sections indicating tumor metastasis. For each transplanted group, metastatic tumor cells to 
the lymph node was quantified (N = 6). Bar = 200 μm. (f) Western blot analysis indicating 
phosphorylation status of LIMK1 and LIMK2 in control and MDA-SEMA3B cell extracts. 
Total LIMK1 and LIMK2 indicate equal loading of samples. Protein bands 72 kDa.
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